Cargando…

27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice

ABSTRACT IMPACT: This work may lead to new treatments for crystalline nephropathies. OBJECTIVES/GOALS: This study investigated obeticholic acid (OCALIVA ®) as a potential treatment for 2,8-dihydroxyadenine (2,8-DHA) nephropathy using a mouse model. The treatment was investigated in both sexes at two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Bryce, Benitez, Carlos, Cruz, Idalia, Myakala, Komuraiah, Wang, Xiaoxin, Libby, Andrew, Rowland, Emma, Kurtz, Ryan, Rosenberg, Avi, Levi, Moshe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827674/ http://dx.doi.org/10.1017/cts.2021.428

Ejemplares similares

4528 Sirtuin 3 activation as a potential renoprotective therapy in a mouse model of Alport syndrome
por: Jones, Bryce, et al.
Publicado: (2020)

SRGAP2a: A New Player That Modulates Podocyte Cytoskeleton and Injury in Diabetes
por: Levi, Moshe, et al.
Publicado: (2018)

Fibrosis quantification using multiphoton excitation imaging of picrosirius red stained cardiac tissue
por: Jones, Bryce A., et al.
Publicado: (2023)

Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression
por: Oshima, Yoichi, et al.
Publicado: (2023)

Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation
por: Nanmoku, Koji, et al.
Publicado: (2017)

Dihydroxyadenine crystal-induced nephropathy presenting with rapidly progressive renal failure
por: Verma, Ritu, et al.
Publicado: (2018)

Recurrence of 2,8-dihydroxyadenine Crystalline Nephropathy in a Kidney Transplant Recipient: A Case Report and Literature Review
por: Cheng, Yamei, et al.
Publicado: (2021)

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
por: Wang, Dong, et al.
Publicado: (2018)

Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
por: Wang, Dong, et al.
Publicado: (2017)

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice
por: Kurtz, Ryan, et al.
Publicado: (2022)

Dihydroxyadenine stone with adenine phosphoribosyltransferase deficiency: A case report
por: Krishnappa, Pramod, et al.
Publicado: (2017)

PodoCount: A Robust, Fully Automated, Whole-Slide Podocyte Quantification Tool
por: Santo, Briana A., et al.
Publicado: (2022)

2, 8 Dihydroxyadenine urolithiasis: A case report and review of literature
por: Sreejith, P., et al.
Publicado: (2009)

Kidney Biopsy Techniques to Differentiate Calcium Oxalate and Dihydroxyadenine Tubular Crystals
por: Ibrahim, Dalia, et al.
Publicado: (2022)

The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice
por: Wang, Xiaoxin X., et al.
Publicado: (2022)

Lactobacillus helveticus (ATCC 27558) upregulates Runx2 and Bmp2 and modulates bone mineral density in ovariectomy-induced bone loss rats
por: Parvaneh, Maria, et al.
Publicado: (2018)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

A user-friendly tool for cloud-based whole slide image segmentation with examples from renal histopathology
por: Lutnick, Brendon, et al.
Publicado: (2022)

NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease
por: Myakala, Komuraiah, et al.
Publicado: (2023)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2018)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes
por: McIlvride, Saraid, et al.
Publicado: (2019)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
por: John, Binu V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f54lu36qnq80hqvq8u3hetghrj